![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression PR Newswire CAMBRIDGE...
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., June 24, 2024 Following positive 6-month clinical outcomes from phase 2b...
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal PR Newswire CAMBRIDGE, Mass., June 21, 2024 CAMBRIDGE, Mass., June 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd...
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit PR Newswire CAMBRIDGE, Mass., May 20, 2024 CAMBRIDGE, Mass., May 20, 2024...
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning PR Newswire CAMBRIDGE, Mass., May 14, 2024 PhaseV's Causal Machine Learning Predicts...
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients PR...
NeuroSense Announces First Quarter 2024 Business Update PR Newswire CAMBRIDGE, Mass., May 2, 2024 CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN...
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease PR Newswire CAMBRIDGE, Mass., April 22, 2024 CAMBRIDGE...
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting PR Newswire CAMBRIDGE, Mass., April...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.14 | -12.8440366972 | 1.09 | 1.5 | 0.9067 | 929401 | 1.23958909 | CS |
4 | -0.09 | -8.65384615385 | 1.04 | 1.5 | 0.698 | 373939 | 1.14713968 | CS |
12 | -0.58 | -37.908496732 | 1.53 | 1.73 | 0.698 | 185618 | 1.19482685 | CS |
26 | 0.11 | 13.0952380952 | 0.84 | 2.33 | 0.698 | 250721 | 1.42551017 | CS |
52 | -0.39 | -29.1044776119 | 1.34 | 2.33 | 0.4 | 353880 | 1.10528479 | CS |
156 | -3.6 | -79.1208791209 | 4.55 | 8.18 | 0.4 | 1098384 | 3.51910181 | CS |
260 | -3.6 | -79.1208791209 | 4.55 | 8.18 | 0.4 | 1098384 | 3.51910181 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions